Loading clinical trials...
Loading clinical trials...
This study is conducted to select the THR-687 dose level (Part A of the study) and to assess the efficacy and safety of the selected dose level compared to aflibercept (Part B of the study).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Oxurion
NCT06613854 · Type 2 Diabetes Mellitus (T2DM)
NCT07535307 · Diabetes Mellitus
NCT07425522 · Diabetic Macular Edema
NCT07224321 · Type 1 Diabetes Mellitus
NCT06862739 · Diabetes Mellitus, Type 2 DM
Salehi Retina Institute Inc.
Huntington Beach, California
California Eye Specialists Medical Group, Inc.
Pasadena, California
Retinal Consultants Medical Group
Sacramento, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions